Now Available:
Download podcasts from the 2008 ISEMIR conference

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Report Coverage of the 2008 EULAR Congress:

EULAR 2008: Visit MSK Report's dedicated EULAR 2008 page for complete coverage of the 2008 Annual European Congress of Rheumatology, including news briefs and press conference videos

EULAR 2008: Step-Up, Tight Control Abates Early RA in 50% of Patients by 36 Weeks
As many as half of all early rheumatoid arthritis patients may achieve remission within 36 weeks following step-up therapy coupled with tight control...

EULAR 2008: How to Tell If an RA Patient is Likely to Achieve DMARD-Free Remission Without Biologics
A number of factors identify rheumatoid arthritis patients whose disease is likely to respond to conventional DMARD treatment with sustained, drug-free remission...

Pain: Sound, Pressure Show General CNS Sensory Changes in FM
FM patients have a general CNS augmentation of sensory information, not just abnormal pain processing...

Arthritis: Increased Melanoma Risk Seen in RA Patients Taking MTX
Rheumatoid arthritis (RA) patients taking methotrexate (MTX) may be at a 3-fold increased risk for developing potentially fatal melanoma...

Arthritis: Meniscal Damage, Joint Malalignment Predict Cartilage Loss in Knee OA
New research confirms that meniscal damage and joint alignment predict cartilage loss in knee osteoarthritis (OA)...

BioPharm Business: Merck Announces Initiation of Second Phase II/III Pivotal Clinical Study of Atacicept in SLE
Merck and development partner ZymoGenetics have initiated a phase II/III trial of atacicept (formerly TACI-Ig) in patients with systemic lupus erythematosus (SLE). Atacicept inhibits the two growth factors BLyS and APRIL that are known to impact disease progression...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .